A Chinese DADA2 patient: report of two novel mutations and successful HSCT

  • Luyao Liu
  • Wenjie Wang
  • Ying Wang
  • Jia Hou
  • Wenjing Ying
  • Xiaoying Hui
  • Qinhua Zhou
  • Danru Liu
  • Haili Yao
  • Jinqiao SunEmail author
  • Xiaochuan WangEmail author
Original Paper


Deficiency of adenosine deaminase 2 (DADA2) is an autoinflammatory disease caused by autosomal recessive mutations in Cat Eye Syndrome Chromosome Region 1 (CECR1) gene. In this report, we aimed to describe the clinical manifestations, immunological features, genotype, and treatments of one Chinese patient with novel CECR1 gene mutations. This patient initially presented with recurrent fever and rashes from the age of 3 months, but no pathogen was found. She then developed dry gangrene of the fingers at 5 months of age. Laboratory examinations revealed elevated levels of C-reactive protein and thrombocytes. The expression of interleukin-6 (IL-6) and IL-8 were both elevated. Sequencing results revealed that she had compound heterozygous mutations in CECR1 gene (c.1211T>C, p.Phe404Ser and c.1114 G>A, p.Val372Met). Subsequently, treatment with anti-IL-6 (tocilizumab) was started. However, she developed blurred vision in the right eye with occlusion of the central retinal artery, accompanied by unsteady gait. Magnetic resonance imaging (MRI) showed infarction of the right thalamus. Finally, she underwent hematopoietic stem cell transplantation (HSCT) and is currently in remission. Our findings suggest that HSCT could cure this disease.


Adenosine deaminase 2 deficiency CECR1 gene Novel mutations Hematopoietic stem cell transplantation 



Many thanks to the patient and her parents.


This study was funded by the National Natural Science Foundation of China (81471482), Science and Technology Commission of Shanghai Municipality (14411965400), and Shanghai Hospital Development Center (SHDC12016228).

Compliance with ethical standards

The study was approved by the Ethics Committee of the Children’s Hospital of Fudan University. The patient’s parents gave written informed consent.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

251_2018_1101_MOESM1_ESM.xlsx (13 kb)
ESM 1 (XLSX 12 kb)


  1. Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Picard C, Puck JM, Sullivan KE, Tang ML (2015) The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol 35:727–738. CrossRefGoogle Scholar
  2. Bucciol G, Delafontaine S, Segers H, Bossuyt X, Hershfield MS, Moens L, Meyts I (2017) Hematopoietic stem cell transplantation in ADA2 deficiency: early restoration of ADA2 enzyme activity and disease relapse upon drop of donor Chimerism. J Clin Immunol 37:746–750. CrossRefGoogle Scholar
  3. Caorsi R, Penco F, Schena F, Gattorno M (2016) Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J 14(51).
  4. Debatin KM (2017) HSCT cures ADA2 deficiency. Blood 130:2582–2583. CrossRefGoogle Scholar
  5. Fellmann F, Angelini F, Wassenberg J, Perreau M, Arenas Ramirez N, Simon G, Boyman O, Demaria O, Christen-Zaech S, Hohl D, Belfiore M, von Scheven-Gete A, Gilliet M, Bochud PY, Perrin Y, Beck Popovic M, Bart PA, Beckmann JS, Martinet D, Hofer M (2016) IL-17 receptor a and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol 137:1189–1196. CrossRefGoogle Scholar
  6. Gonzalez Santiago TM, Zavialov A, Saarela J, Seppanen M, Reed AM, Abraham RS, Gibson LE (2015) Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol 151:1230–1234. CrossRefGoogle Scholar
  7. Hashem H, Kelly SJ, Ganson NJ, Hershfield MS (2017a) Deficiency of adenosine deaminase 2 (DADA2), an inherited cause of polyarteritis nodosa and a mimic of other systemic rheumatologic disorders. Curr Rheumatol Rep 19:70. CrossRefGoogle Scholar
  8. Hashem H, Kumar AR, Müller I, Babor F, Bredius R, Dalal J, Hsu AP, Holland SM, Hickstein DD, Jolles S, Krance R, Sasa G, Taskinen M, Koskenvuo M, Saarela J, van Montfrans J, Wilson K, Bosch B, Moens L, Hershfield M, Meyts I (2017b) Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood 130:2682–2688. CrossRefGoogle Scholar
  9. Meyts I, Aksentijevich I (2018) Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol 38:569–578. CrossRefGoogle Scholar
  10. Michniacki TF, Hannibal M, Ross CW, Frame DG, DuVall AS, Khoriaty R, Vander Lugt MT, Walkovich KJ (2018) Hematologic manifestations of deficiency of adenosine Deaminase 2 (DADA2) and response to tumor necrosis factor inhibition in DADA2-associated bone marrow failure. J Clin Immunol 38:166–173. CrossRefGoogle Scholar
  11. Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S, Ekelund M, Jolles S, Harper L, Youngstein T, Gilmour K, Klein NJ, Eleftheriou D, Brogan PA (2016) Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheum 68:2314–2322. CrossRefGoogle Scholar
  12. Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370:921–931. CrossRefGoogle Scholar
  13. Savic S, McDermott MF (2015) Clinical genetics in 2014: new monogenic diseases span the immunological disease continuum. Nat Rev Rheumatol 11:67–68. CrossRefGoogle Scholar
  14. Sun J, Wang Y, Liu D, Yu Y, Wang J, Ying W, Wang X (2012) Prenatal diagnosis of X-linked chronic granulomatous disease by percutaneous umbilical blood sampling. Scand J Immunol 76:512–518. CrossRefGoogle Scholar
  15. Van Eyck L Jr, Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L, Frans G, Schaballie H, De Hertogh G, Dooley J, Bossuyt X, Wouters C, Liston A, Meyts I (2015) Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol 135:283–287.e5. CrossRefGoogle Scholar
  16. Van Eyck L, Liston A, Meyts I (2014) Mutant ADA2 in vasculopathies. N Engl J Med 371:478–479. CrossRefGoogle Scholar
  17. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CCR, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370:911–920. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Clinical ImmunologyChildren’s Hospital of Fudan UniversityShanghaiChina

Personalised recommendations